Brian P Kearney
Overview
Explore the profile of Brian P Kearney including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
1867
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
German P, Mathias A, Brainard D, Kearney B
Clin Pharmacokinet
. 2018 Apr;
57(11):1369-1383.
PMID: 29644537
Ledipasvir/sofosbuvir (Harvoni), a fixed-dose combination tablet of an NS5A inhibitor ledipasvir and an NS5B polymerase inhibitor sofosbuvir, is approved for the treatment of chronic hepatitis C virus infection. Ledipasvir/sofosbuvir exhibits...
12.
Lutz J, Kirby B, Wang L, Song Q, Ling J, Massetto B, et al.
Clin Pharmacol Ther
. 2018 Mar;
104(6):1182-1190.
PMID: 29569723
Drug transporter and cytochrome P450 expression is regulated by shared nuclear receptors and, hence, an inducer should induce both, although the magnitude may differ. The objective of this study was...
13.
Lutz J, Kirby B, Wang L, Song Q, Ling J, Massetto B, et al.
Clin Pharmacol Ther
. 2018 Mar;
104(6):1191-1198.
PMID: 29569712
Rifampin demonstrated dose-dependent relative induction between cytochrome P (CYP)3A and P-glycoprotein (P-gp), organic anion transporting polypeptides (OATPs), or CYP2C9; P-gp, OATP, and CYP2C9 induction was one drug-drug interaction (DDI) category...
14.
German P, Mathias A, Brainard D, Song Q, Ling J, Kearney B
Clin Pharmacol Drug Dev
. 2017 Oct;
7(6):641-651.
PMID: 29058821
This study evaluated the effect of supratherapeutic exposure of the anti-HCV drug ledipasvir on the QTc interval in healthy subjects. Sixty healthy volunteers were randomized to receive twice-daily blinded ledipasvir...
15.
Custodio J, Chuck S, Chu H, Cao H, Ma G, Flaherty J, et al.
Pharmacol Res Perspect
. 2017 Oct;
5(5).
PMID: 28971607
The drug-drug interaction (DDI) potential between the fixed-dose combinations of ledipasvir/sofosbuvir 90/400 mg for hepatitis C virus and emtricitabine/rilpivirine/tenofovir alafenamide (TAF) 200/25/25 mg for HIV was evaluated in a randomized,...
16.
Mogalian E, German P, Kearney B, Yang C, Brainard D, Link J, et al.
Antimicrob Agents Chemother
. 2017 Feb;
61(5).
PMID: 28193657
Preclinical characterization of velpatasvir (VEL; GS-5816), an inhibitor of the hepatitis C virus (HCV) NS5A protein, demonstrated that it has favorable and properties, including potent antiviral activity against hepatitis C...
17.
Ramanathan S, Di Paolo J, Jin F, Shao L, Sharma S, Robeson M, et al.
Clin Drug Investig
. 2016 Oct;
37(2):195-205.
PMID: 27785737
Background And Objectives: Entospletinib is a selective, reversible, adenosine triphosphate-competitive small-molecule spleen tyrosine kinase (SYK) inhibitor that blocks B cell receptor-mediated signaling and proliferation in B lymphocytes. This study evaluated...
18.
Custodio J, Fordyce M, Garner W, Vimal M, Ling K, Kearney B, et al.
Antimicrob Agents Chemother
. 2016 May;
60(9):5135-40.
PMID: 27216057
Tenofovir alafenamide (TAF) is an oral prodrug of tenofovir (TFV) that has greater stability in plasma than TFV disoproxil fumarate (TDF) and circulates as intact TAF, resulting in the direct...
19.
German P, Mathias A, Brainard D, Kearney B
Clin Pharmacokinet
. 2016 May;
55(11):1337-1351.
PMID: 27193156
Ledipasvir/sofosbuvir (Harvoni), a fixed-dose combination tablet of an NS5A inhibitor ledipasvir and an NS5B polymerase inhibitor sofosbuvir, is approved in the US, European Union, Canada, and other regions for the...
20.
Ramanathan S, Custodio J, Wei X, Wang H, Fordyce M, Dave A, et al.
J Acquir Immune Defic Syndr
. 2016 Feb;
72(3):281-8.
PMID: 26885802
Background: Elvitegravir (EVG), a HIV integrase inhibitor, is metabolized primarily by CYP3A, and secondarily by UGT1A1/3; Efavirenz (EFV), a HIV non-nucleoside reverse transcriptase inhibitor, is metabolized by Cytochrome P450 (CYP)...